Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Doxorubicin-vincristine therapy for Wilms' tumor: a pilot study. Cancer Treat Rep 1982 Oct;66(10):1791-4 PMID: 6290049

Pubmed ID

6290049

Abstract

Doxorubicin plus vincristine chemotherapy was given to 31 children following nephrectomy for Wilms' tumor. Radiation therapy was used as indicated. Disease-free survival by stage is: eight of nine patients (stage I), eight of nine (stage II), nine of ten (stage III), and two of three (stage IV). Median follow-up of survivors is 28 months (range, 2-67); for all but four patients, follow-up is greater than 12 months. Two of the three stage I-III failures occurred in children with unfavorable histologies; the third failure was due to fatal anthracycline cardiomyopathy. Lowering the maximal cumulative doxorubicin dose from 450 to 240 mg/m2 did not increase failures. Doxorubicin-vincristine appears to be effective chemotherapy for Wilms' tumor.

Author List

Camitta B, Kun L, Glicklich M, Oechler H, Adair S, Pinkel D

Author

Bruce M. Camitta MD Clinical Professor in the Medicine department at Medical College of Wisconsin




Scopus

2-s2.0-0019931825   1 Citations

MESH terms used to index this publication - Major topics in bold

Adolescent
Child
Child, Preschool
Doxorubicin
Drug Evaluation
Drug Synergism
Drug Therapy, Combination
Female
Humans
Infant
Male
Nephrectomy
Vincristine
Wilms Tumor
jenkins-FCD Prod-353 9ccd8489072cb19f5b9f808bb23ed672c582f41e